Gene Expression Profile Identifies Tyrosine Kinase C-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-1281
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Molecular Imaging of C-Met Tyrosine Kinase Activity

Analytical Biochemistry
BiochemistryCell BiologyMolecular BiologyBiophysics
2011English

Aerodigestive Fistula Formation as a Rare Side Effect of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Thyroid Cancer

Thyroid
MedicineEndocrinologyMetabolismDiabetes
2014English

Discovery of New Thiophene, Pyrazole, Isoxazole Derivatives as Antitumor, C-Met, Tyrosine Kinase and Pim-1 Kinase Inhibitors

Bulletin of the Chemical Society of Ethiopia
Chemistry
2018English

P2.06-42 AXL, C-Met and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Targeting C-Met Receptor Tyrosine Kinase by the DNA Aptamer SL1 as a Potential Novel Therapeutic Option for Myeloma

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2018English

Non-Receptor Protein-Tyrosine Kinases as Molecular Targets for Antiangiogenic Therapy (Review)

International Journal of Molecular Medicine
MedicineGenetics
2007English

Angiogenic and Antiangiogenic Gene Therapy

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2005English

Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy

Cancer Research
Cancer ResearchOncology
2009English

A Basic Residue C-Terminal to Tyrosine Compromises Its Viability as a Tyrosine Kinase Target

Biochemical Society Transactions
Biochemistry
1995English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy